NEW YORK (GenomeWeb News) – PerkinElmer announced today that it has purchased several radiochemical-related reagent assets from GE Healthcare.
Under the agreement, PerkinElmer will obtain GE Healthcare's 3H and 14C catalog radiochemicals, along with its Scintillation Proximity Assay (SPA) reagents and Cytostar-T plate product lines.
Catalog radiochemicals are used for a variety of research purposes including binding assays that may reveal possible drug candidates. The SPA and Cytostar-T plate products, meanwhile, allow high-throughput screening for such interactions.
The two companies plan to work together during the transition phase to transfer over the manufacturing and technical support related to these products, while minimizing the disruption that customers experience, said PerkinElmer.
PerkinElmer claims that the acquisition will provide it with the largest collection yet of radiolabeled research compounds. The company hopes that by offering a line of readers, nuclear counters, and other instruments that are suited to radiometric detection it can maintain a strong position in the radiochemical field as well as research that relies on these products.
"We expect that the incorporation of these technologies will strengthen our industry-leading [G-protein coupled receptor] and kinase research product lines, and complement our [high-throughput screening] and research reagent solutions," Richard Eglen, president of Bio-discovery for PerkinElmer, said in a statement.
Financial terms of the agreement were not disclosed.